CS
KITE

Candriam SCA’s Kite Pharma, Inc. KITE Stock Holding History

Candriam SCA’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-57,550
Closed -$5.97M – 762
2017
Q2 		$5.97M Sell
57,550
-49,000
-46% -$4M 0.11% 216
2017
Q1 		$8.36M Sell
106,550
-130,000
-55% -$8.04M 0.16% 163
2016
Q4 		$10.6M Buy
236,550
+117,000
+98% +$5.74M 0.24% 111
2016
Q3 		$6.68M Sell
119,550
-60,000
-33% -$3.34M 0.16% 152
2016
Q2 		$8.98M Buy
179,550
+41,050
+30% +$2.02M 0.23% 112
2016
Q1 		$6.32M Buy
138,500
+12,500
+10% +$605K 0.16% 152
2015
Q4 		$7.76M Buy
126,000
+37,800
+43% +$2.66M 0.21% 127
2015
Q3 		$4.91M Buy
88,200
+16,200
+23% +$1.02M 0.12% 208
2015
Q2 		$4.39M Sell
72,000
-8,000
-10% -$456K 0.09% 257
2015
Q1 		$4.62M Buy
80,000
+8,000
+11% +$536K 0.09% 268
2014
Q4 		$4.15M Buy
+72,000
New +$3.03M 0.09% 265

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Candriam SCA's KITE Position: Q3 2017 in Review

Candriam SCA sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 57,550 shares — an estimated $5.97M sold.

Candriam SCA first reported a position in KITE in Q4 2014 and held it in 11 quarters. The position peaked at $10.6M in Q4 2016. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Candriam SCA reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Candriam SCA sold 57,550 Kite Pharma, Inc. shares in Q3 2017, an estimated $5.97M.
  • Candriam SCA first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 11 quarters.
  • Candriam SCA's Kite Pharma, Inc. position peaked at $10.6M in Q4 2016.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Candriam SCA's 13F filing for Q3 2017, filed 3 Nov 2017.